Regeneron Pharmaceuticals (NASDAQ:REGN) Stock: Insider Kathryn Guarini Sells 400 Shares

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Director Kathryn Guarini sold 400 shares of the company’s stock in a transaction on Friday, October 30th. The stock was sold at an average price of $900.00, for a total transaction of $360,000.00. Following the completion of the sale, the director owned 603 shares of the company’s stock, valued at $542,700. This represents a 39.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kathryn Guarini also recently made the following trade(s):

• On Wednesday, September 2nd, Kathryn Guarini sold 400 shares of Regeneron Pharmaceuticals stock. The stock was sold at an average price of $850.00, for a total transaction of $340,000.00.
• On Monday, August 10th, Kathryn Guarini sold 400 shares of Regeneron Pharmaceuticals stock. The shares were sold at an average price of $800.00, for a total value of $320,000.00.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN opened at $930.67 on Thursday. The stock has a market capitalization of $95.82 billion, a P/E ratio of 20.55, a P/E/G ratio of 1.45 and a beta of 0.10. The business has a 50-day moving average of $800.69 and a two-hundred day moving average of $741.11. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $591.52 and a fifty-two week high of $991.73. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.35 and a quick ratio of 3.66.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Friday, October 30th. The biopharmaceutical company reported $20.07 EPS for the quarter, beating analysts’ consensus estimates of $16.51 by $3.56. Regeneron Pharmaceuticals had a return on equity of 16.01% and a net margin of 28.51%. The business had revenue of $5.12 billion for the quarter, compared to analyst estimates of $4.58 billion. During the same quarter in the prior year, the firm posted $11.83 EPS. The firm’s revenue for the quarter was up 36.3% on a year-over-year basis. On average, equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 51.64 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 3rd. Shareholders of record on Friday, November 20th will be issued a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.4%. The ex-dividend date is Friday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 8.30%.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Bank of America added REGN to its Value 10 list, a favorable signal about the stock’s value appeal. BofA adds REGN to Value 10 list
• Positive Sentiment: Recent analyst coverage points to higher price targets and expectations for appreciation. Separately, Zacks said solid earnings-estimate revisions could help the shares continue gaining. These views follow Regeneron’s recent quarterly results, which beat consensus on earnings and revenue. RBC raises Regeneron price target Zacks on earnings estimate revisions
• Negative Sentiment: Recent disclosures show EVP Joseph Larosa sold 4,466 shares and director Christine Poon sold 7,830 shares on November 2; Poon’s sale cut her direct holding by 60%. Director Kathryn Guarini also sold 400 shares under a pre-arranged trading plan. The larger transactions could raise concerns about insider sentiment, though sales alone do not indicate a change in the company’s business outlook. Larosa sale filing Poon sale filing Guarini sale filing

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. bought a new stake in Regeneron Pharmaceuticals in the second quarter valued at approximately $5,682,636,000. State Street Corp boosted its position in shares of Regeneron Pharmaceuticals by 3.6% during the second quarter. State Street Corp now owns 4,834,688 shares of the biopharmaceutical company’s stock worth $3,014,621,000 after purchasing an additional 170,210 shares in the last quarter. Bank of America Corp DE boosted its position in shares of Regeneron Pharmaceuticals by 2.8% during the first quarter. Bank of America Corp DE now owns 1,189,584 shares of the biopharmaceutical company’s stock worth $919,120,000 after purchasing an additional 32,158 shares in the last quarter. Amundi grew its holdings in shares of Regeneron Pharmaceuticals by 27.5% in the 1st quarter. Amundi now owns 1,009,798 shares of the biopharmaceutical company’s stock valued at $780,210,000 after buying an additional 217,892 shares during the period. Finally, Legal & General Group Plc bought a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at $473,872,000. 83.31% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of analysts have recently weighed in on REGN shares. Leerink Partners boosted their price objective on shares of Regeneron Pharmaceuticals from $835.00 to $997.00 and gave the stock a “market perform” rating in a research note on Monday. Robert W. Baird raised their target price on shares of Regeneron Pharmaceuticals from $761.00 to $875.00 and gave the company a “neutral” rating in a research note on Monday. Argus upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $850.00 target price on the stock in a report on Thursday, October 1st. Royal Bank Of Canada boosted their target price on shares of Regeneron Pharmaceuticals from $810.00 to $913.00 and gave the stock a “sector perform” rating in a research report on Monday. Finally, Wells Fargo & Company upped their price target on shares of Regeneron Pharmaceuticals from $750.00 to $925.00 and gave the company an “equal weight” rating in a report on Monday. One analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $898.97.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.